Merakris Therapeutics, Inc.

Merakris Therapeutics, Inc. company information, Employees & Contact Information

A pioneer in biotechnology, Merakris Therapeutics, based in Research Triangle Park, North Carolina, is a leader in researching, developing, and marketing regenerative healthcare products. We are pioneering commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Our vision is to improve global patient care and outcomes through the pioneering and innovation of cellular regenerative biotechnologies. Merakris Therapeutics strives to: • Be a leader in the research and development of regenerative medicine. • Deliver effective medical therapies that require fewer treatments and help to improve patient outcomes, while reducing the overall cost of care. • Educate patients and healthcare providers about the benefits of alternative therapies and regenerative medicine in comparison to standard or more invasive treatment options.

Company Details

Employees
27
Founded
-
Address
800 Park Offices Drive,
Phone
+ 1 919 921 8105
Email
in****@****ris.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Research Triangle Park, NC
Looking for a particular Merakris Therapeutics, Inc. employee's phone or email?

Merakris Therapeutics, Inc. Questions

News

Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway - GlobeNewswire

Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway GlobeNewswire

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit - GlobeNewswire

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit GlobeNewswire

Merakris Therapeutics Receives USPTO Notice of Allowance - GlobeNewswire

Merakris Therapeutics Receives USPTO Notice of Allowance GlobeNewswire

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid - Yahoo Finance

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid Yahoo Finance

International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers - Yahoo Finance

International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers Yahoo Finance

Merakris Therapeutics Announces Open Enrollment for Phase - GlobeNewswire

Merakris Therapeutics Announces Open Enrollment for Phase GlobeNewswire

(PDF) A DOUBLE-HEADER: DRY EYE AND FILAMENTARY KERATITIS - researchgate.net

(PDF) A DOUBLE-HEADER: DRY EYE AND FILAMENTARY KERATITIS researchgate.net

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care - Yahoo Finance

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care Yahoo Finance

Top Merakris Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant